Unraveling the obesity paradox in small cell lung cancer immunotherapy: unveiling prognostic insights through body composition analysis
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Obesity and body composition impact small cell lung cancer (SCLC) immunotherapy. High adiposity worsens sarcopenia effects, while body shape index (BSI) shows potential as a prognostic marker.
Area Of Science
- Oncology
- Immunotherapy
- Radiology
Background
- Immunotherapy has transformed small cell lung cancer (SCLC) treatment.
- Identifying reliable prognostic biomarkers for SCLC immunotherapy remains challenging.
- Investigating obesity and body composition as prognostic factors in SCLC immunotherapy is crucial.
Purpose Of The Study
- To explore the prognostic implications of obesity and body composition in SCLC patients undergoing immunotherapy.
- To identify a simple anthropometric measure for predicting outcomes in SCLC immunotherapy.
- To analyze the relationship between body composition metrics and treatment response, progression-free survival (PFS), and overall survival (OS).
Main Methods
- Retrospective analysis of 145 SCLC patients treated with immunotherapy (2019-2023).
- Body composition and waist circumference (WC) analyzed from baseline CT scans using 3D slicer software.
- Quantitative measures including skeletal muscle index (SMI), total adipose tissue index (TATI), and body shape index (BSI) were assessed.
Main Results
- Body mass index (BMI) ≥28 kg/m² showed a PFS advantage in univariate analysis, but not in multivariate analysis.
- Body shape index (BSI) demonstrated the strongest correlation with muscle composition.
- Lower BSI was significantly associated with poorer overall survival (OS) in multivariate analysis (HR 1.79, p=0.02).
- High total adipose tissue (TATI) exacerbated the negative prognostic effect of low skeletal muscle index (SMI).
Conclusions
- No clear association between BMI and SCLC immunotherapy prognosis was found.
- High adiposity amplifies the adverse effects of sarcopenia in SCLC immunotherapy.
- Body shape index (BSI) shows promise as a simple anthropometric prognostic tool for SCLC immunotherapy.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
